New York Chronicle

Delveinsight Business Research LLP

Some of the key players actively working in the COPD market include AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others. The Chronic Obstructive Pulmonary Disease (COPD) pipeline possesses potential drugs in mid-stage developments to be launched in the near future. Itepekimab, Ensifentrine (RPL554), Dupilumab, Benralizumab, Mepolizumab and Acumapimod shall further create a positive impact on the market.

DelveInsight’s “Chronic Obstructive Pulmonary Disease (COPD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Obstructive Pulmonary Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Chronic Obstructive Pulmonary Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Obstructive Pulmonary Disease (COPD): An Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

In the United States, the term COPD includes two main conditions—emphysema and chronic bronchitis. In emphysema, the walls between many of the air sacs are damaged. As a result, the air sacs lose their shape and become floppy. This damage also can destroy the walls of the air sacs, leading to fewer and larger air sacs instead of many tiny ones. If this happens, the amount of gas exchange in the lungs is reduced.

The main risk factor for COPD is tobacco smoking, but other environmental exposures, such as biomass fuel exposure and air pollution, may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development, and accelerated aging.

Chronic Obstructive Pulmonary Disease (COPD) Market Key Facts

• The Chronic Obstructive Pulmonary Disease therapeutic market in the United States was USD 9,379 million in the year 2020.

• The United States accounts for the largest Chronic Obstructive Pulmonary Disease market size compared to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

• Among the EU5 countries, Germany had the highest Chronic Obstructive Pulmonary Disease market size, while the UK had the lowest market size for COPD.

• The therapeutic market of COPD in Japan was USD 361 million in the year 2020.

• The diagnosed prevalent cases of COPD in the 7MM were 34,640,000+ in 2020. 

• The estimates suggest a higher diagnosed prevalence of COPD in the United States, with 17,455,605 diagnosed cases in 2020.

• In 2020, a lower number of males were affected by this disease, contributing 6,588,000+ diagnosed prevalent COPD population in the United States. In comparison, there were 10,867,000+ females affected by COPD in 2020 in the US.

• The majority of cases of COPD are female in the US. But in EU-5 and Japan, the diagnosed cases of COPD in males represent the majority of the cases. Overall, in the 7MM, females are predominantly high.

• Germany has the highest diagnosed prevalent population among the five major European countries, followed by Italy and France. On the other hand, Spain had the lowest diagnosed prevalent population.

Chronic Obstructive Pulmonary Disease (COPD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Chronic Obstructive Pulmonary Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Chronic Obstructive Pulmonary Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Chronic Obstructive Pulmonary Disease (COPD) Epidemiology, Segmented as –

• Diagnosed Prevalent cases of COPD in the 7MM [2019–2032]

• Gender-specific Diagnosed Prevalent cases of COPD in the 7MM [2019–2032]

• Diagnosed Prevalent Cases of COPD Based on Severity of Airflow in the 7MM [2019–2032]

• Age-specific Diagnosed Prevalent cases of COPD in the 7MM [2019–2032]

• Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History COPD in the 7MM [2019–2032]

Chronic Obstructive Pulmonary Disease (COPD) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Obstructive Pulmonary Disease market or expected to be launched during the study period. The analysis covers the Chronic Obstructive Pulmonary Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Obstructive Pulmonary Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Chronic Obstructive Pulmonary Disease Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

Chronic Obstructive Pulmonary Disease (COPD)  Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Chronic Obstructive Pulmonary Disease. Currently, AstraZeneca is leading the therapeutics market with its Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage of clinical development.

The Leading in the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Include:

Amgen, AstraZeneca, Biomarck Pharmaceuticals, Boehringer Ingelhe,im Pharmaceuticals, Chiesi, Chiesi Farmaceutici, Circassia Pharmaceuticals Inc., Eisai, EmeraMed Limited, Genentech, GlaxoSmithKline, Theravance, Inc/Innoviva, Inmunotek, Mereo BioPharma, Meridigen Biotech, Novartis Pharmaceuticals, Organicell Regenerative Medicine, Pulmotect Inc., Regeneron Pharmaceuticals, Sanofi, Sunovion Pharmaceuticals, Synairgen, Tetherex Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, and others.

Chronic Obstructive Pulmonary Disease (COPD) Therapies Covered in the Report Include:

• Acumapimod (BCT-197): Mereo BioPharma

• Advair Diskus/Adoair Diskus/Seretide Diskus (Fluticasone Propionate and Salmeterol Xinafoate): GlaxoSmithKline

• Anoro Ellipta (Umeclidinium Bromide and Vilanterol Trifenatate): GlaxoSmithKline/Theravance

• Azithromycin: Genentech

• Benlysta (Belimumab): GlaxoSmithKline

• Bevespi Aerosphere (Glycopyrronium/Formoterol Fumarate): AstraZeneca

• BIO-11006 Inhalation Solution: Biomarck Pharmaceuticals

• Breo Ellipta/Relvar Ellipta (Fluticasone Furoate and Vilanterol): GlaxoSmithKline

• Breztri Aerosphere/Trixeo Aerosphere (Budesonide/Glycopyrrolate/Formoterol Fumarate): AstraZeneca

• Brovana (Arformoterol tartrate): Sunovion Pharmaceuticals

• CHF6001 (Tanimilast): Chiesi Farmaceutici S.p.A.

• Duaklir Pressair/Duaklir Genuair (Aclidinium Bromide and Formoterol Fumarate): AstraZeneca/Circassia Pharmaceuticals Inc.

• Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi

• Eklira Genuair/Tudorza Pressair/Betrays Genuair (Aclidinium Bromide Inhalation Powder): AstraZeneca

• Ensifentrine (RPL554): Verona Pharma PLC

• Epeleuton (DS102): Afimmune

• Fasenra (Benralizumab): AstraZeneca

• Icenticaftor (QBW251): Novartis Pharmaceuticals

• Incruse Ellipta/Encruse Ellipta (Umeclidinium Inhalation Powder): GlaxoSmithKline

• Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals

• Kalydeco (Ivacaftor/VX-770): Vertex Pharmaceuticals Incorporated

• MEDI3506: AstraZeneca

• MV130 (Bactek): Inmunotek

• NOV-14 (CSJ117): Novartis Pharmaceuticals

• NTHi Mcat investigational vaccine (GSK3277511A): GlaxoSmithKline

• Nucala (Mepolizumab): GlaxoSmithKline

• PUL-042 Inhalation Solution: Pulmotect Inc.

• SelK2: Tetherex Pharmaceuticals Corporation

• Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder): Boehringer Ingelheim Pharmaceuticals

• Symbicort (Budesonide and Formoterol Fumarate Dihydrate): AstraZeneca

• Tezepelumab: AstraZeneca/Amgen

• Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/ Vilanterol): GlaxoSmithKline

• Trydonis (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate, and Glycopyrronium): Chiesi Farmaceutici

• Tyvaso (Inhaled treprostinil solution): United Therapeutics

• Zofin: Organicell Regenerative Medicine

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Obstructive Pulmonary Disease Competitive Intelligence Analysis

4. Chronic Obstructive Pulmonary Disease Market Overview at a Glance

5. Chronic Obstructive Pulmonary Disease Disease Background and Overview

6. Chronic Obstructive Pulmonary Disease Patient Journey

7. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Chronic Obstructive Pulmonary Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Obstructive Pulmonary Disease Unmet Needs

10. Key Endpoints of Chronic Obstructive Pulmonary Disease Treatment

11. Chronic Obstructive Pulmonary Disease Marketed Products

12. Chronic Obstructive Pulmonary Disease Emerging Drugs and Latest Therapeutic Advances

13. Chronic Obstructive Pulmonary Disease Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Obstructive Pulmonary Disease Market Outlook (In US, EU5, and Japan)

16. Chronic Obstructive Pulmonary Disease Access and Reimbursement Overview

17. KOL Views on the Chronic Obstructive Pulmonary Disease Market

18. Chronic Obstructive Pulmonary Disease Market Drivers

19. Chronic Obstructive Pulmonary Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/